MedTrace Logo

Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy

NCT06072521 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-10-17

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy of lactoferrin as an adjunct therapy in improving clinical symptoms and laboratory indices in individuals with hepatic encephalopathy.

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

Lactoferrin Bovine

Lactoferrin bovine with concentration 100 mg will be given to the patients in test groups in the form of sachets.

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Amin M. Abdel Baki, Doctoral · National hepatology and tropical medicine research institute

  • Nayira A. Abdel Baky, Doctoral · Al-Azhar University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-09-30
Completion
2024-10-31
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06072521 on ClinicalTrials.gov